title: [Fibrinogen concentration in the evaluation of safety and efficiency of thrombolytic therapy in patients with ischemic stroke].
abstract: OBJECTIVE
  To identify and investigate threshold fibrinogen concentrations as predictors of hemorrhagic transformation (HT), fatal outcome (FO), and the efficiency of thrombolytic therapy (TLT) in patients with ischemic stroke (IS).
  
  
  METHODS
  One hundred and eighty-one patients with IS were examined; all the patients received TLT. Fibrinogen concentrations were determined by the Clauss method on admission, immediately after TLT, and daily during the first 7 days of observation; the efficacy of thrombolysis was evaluated using the NIH stroke scale every day, the Rankin scale, and the Barthel Index on days 14 and 21.
  
  
  RESULTS
  The patients with a fibrinogen concentration of below 330 mg/dl showed the lowest frequency of asymptomatic HT (AHT) as hemorrhagic stroke (HS) type 1 in the absence of clinically worsening HT (CWHT), as well as FO and the highest rate of good functional recovery. Those with a fibrinogen concentration of 330-385 mg/dl most commonly displayed AHT as HS types 1 and 2 equally frequently, as well as the highest frequency of a positive effect according to the criteria for good and/or satisfactory functional recoveries. The fibrinogen concentration range of 385-423 mg/dl compared to the above range was characterized by an increased risk for AHT as HS type 2, for CWHT as equally distributed parenchymal hematoma types 1 and 2, by higher death rates and less chance of functional recovery. The elevated fibrinogen concentration above 423 mg/dl was accompanied by high death rates and CWHT as parenchymal hematoma type 2 and the higher frequency of poor outcome in the evaluation of functional recovery.
  
  
  CONCLUSIONS
  The revealed three threshold fibrinogen concentrations of 330, 385, and 423 mg/dl allow one to predict HS, FO, and the efficiency of TLT in patients with IS.
authors.forename: O V
authors.initials: OV
authors.lastname: Liang
authors.forename: A G
authors.initials: AG
authors.lastname: Kochetov
authors.forename: N A
authors.initials: NA
authors.lastname: Shamalov
authors.forename: K V
authors.initials: KV
authors.lastname: Anisimov
authors.forename: G R
authors.initials: GR
authors.lastname: Ramazanov
authors.forename: A A
authors.initials: AA
authors.lastname: Arkhipkin
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Novozhenova
authors.forename: M A
authors.initials: MA
authors.lastname: Kustova
authors.forename: D C
authors.initials: DC
authors.lastname: Podshivalov
authors.forename: V O
authors.initials: VO
authors.lastname: Egorov
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005340:Fibrinogen; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D020127:Recovery of Function; D012720:Severity of Illness Index; D020521:Stroke / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D005340:Fibrinogen